Overview

Pasireotide in Prevention of GI Toxicity

Status:
Completed
Trial end date:
2019-10-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate if the drug, Pasireotide, is safe and effective in reducing the gastrointestinal side effects of the drugs received to prepare for allogeneic stem cell transplant. The study will also evaluate if Pasireotide is effective in reducing acute and chronic Graft-versus-Host-Disease (GvHD) after transplant.
Phase:
Phase 2
Details
Lead Sponsor:
Anthony Sung, MD
Collaborator:
Massachusetts General Hospital
Treatments:
Pasireotide
Somatostatin